Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:
- Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
- Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
- Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
- CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.
In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.
On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.
Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.
Cerevel Therapeutics (CERE) reported a strong cash position of $550.9 million as of March 31, 2022, bolstered by a $37.5 million risk-sharing arrangement in April 2022. The company is on track to initiate two Phase 2 trials for emraclidine in schizophrenia by mid-2022, with results expected in the first half of 2024. Positive results from the darigabat Phase 1 trial were announced, and data from its Phase 2 epilepsy trial is now anticipated in mid-2023. R&D expenses rose to $55.0 million in Q1 2022, reflecting ongoing clinical advancements.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its first quarter 2022 financial results on May 10, 2022, before U.S. markets open. Management will host a conference call at 8:00 a.m. ET to discuss these results and recent business updates. The call can be accessed domestically at (833)-665-0655 or internationally at (702)-495-1044, using conference ID 4497847. A live webcast will be available on the investors section of Cerevel’s website.
Cerevel Therapeutics (Nasdaq: CERE) announced key presentations at the American Academy of Neurology (AAN) Annual Meeting from April 2-7, 2022. Highlights include an oral presentation showcasing preclinical data on darigabat, demonstrating significant antiepileptic effects in drug-resistant focal seizures, comparable to diazepam. The company also revealed findings on tavapadon, a treatment for Parkinson’s disease, emphasizing its consistent pharmacokinetic profile across Phase 1 trials. Cerevel is focused on advancing its neuroscience drug pipeline to address unmet medical needs.
Cerevel Therapeutics (Nasdaq: CERE) announced that its CEO, Tony Coles, M.D., will participate in a fireside chat at the Stifel 4th Annual CNS Day on March 29, 2022, at 9:00 a.m. EDT. The event will highlight the company's commitment to addressing neuroscience diseases through its diversified pipeline, which includes six clinical-stage investigational therapies targeting conditions like schizophrenia and Parkinson’s disease. A live webcast will be available on Cerevel's investor relations website, along with a replay.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat for acute anxiety and is on track to initiate two Phase 2 trials of emraclidine for schizophrenia by mid-2022. The trials will involve 372 patients each, with results expected in the first half of 2024. Cerevel reported a cash position of $618 million as of December 31, 2021, a significant increase from $383.6 million in 2020. R&D expenses rose to $161.9 million, while G&A expenses grew to $58.2 million, reflecting ongoing investments in clinical programs and operations.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter 2021 financial results on March 1, 2022, before U.S. markets open. The company will host a conference call at 8:00 a.m. ET the same day to discuss the results and recent business updates. Interested parties can access the call by dialing designated numbers or via a live webcast on the company's investor website. Cerevel focuses on neuroscience diseases and has a diversified pipeline of investigational therapies.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat, a novel GABAA receptor PAM, showing significant anxiolytic effects in healthy volunteers. Both the 7.5 mg and 25 mg doses demonstrated a statistically significant improvement in Panic Symptoms List scores after eight days compared to placebo. The trial was well-tolerated with no serious adverse events reported. Cerevel plans to advance darigabat for anxiety-related disorders and is also conducting a Phase 2 trial for focal epilepsy. These developments position darigabat as a potential treatment innovation in anxiety management.
Cerevel Therapeutics announces emraclidine as the international nonproprietary name for CVL-231, an M4-selective positive allosteric modulator for schizophrenia. The company plans to initiate a Phase 2 program by mid-2022, with expected data in the first half of 2024. The Phase 1 trial for darigabat in acute anxiety has been completed, with data anticipated shortly. Additionally, the Phase 2a data for CVL-871 in dementia-related apathy is now expected in 1H 2023, delayed from 2H 2022 due to COVID-19. Cerevel's cash is projected to fund operations into 2024.
Cerevel Therapeutics (Nasdaq: CERE) announced that CEO Tony Coles will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. Joining him will be CMO Raymond Sanchez and CSO John Renger for the Q&A session. Investors can access the live webcast on the company's investor relations website, with a replay available afterward. Cerevel focuses on treating neuroscience diseases, possessing a pipeline of six clinical-stage therapies aimed at conditions like Parkinson's, epilepsy, and schizophrenia.
Cerevel Therapeutics (CERE) and Herophilus have initiated a multi-year collaboration focusing on schizophrenia treatment using innovative brain organoids and deep phenotyping technologies. This partnership aims to uncover disease mechanisms and develop therapies that could significantly improve or even reverse schizophrenia symptoms. By integrating human genetics into advanced testing models, they hope to enhance therapeutic discovery and validation processes. Cerevel's pipeline includes multiple clinical-stage therapies targeting various neuroscience diseases, including schizophrenia.
FAQ
What is the current stock price of Cerevel Therapeutics Holdings (CERE)?
What is the market cap of Cerevel Therapeutics Holdings (CERE)?
What does Cerevel Therapeutics Holdings, Inc. specialize in?
When was Cerevel Therapeutics formed?
Where is Cerevel Therapeutics headquartered?
What are some of Cerevel Therapeutics' leading investigational therapies?
What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?
What recent financial achievement has Cerevel accomplished?
What major acquisition was announced involving Cerevel Therapeutics?
What is the expected closing date for the AbbVie acquisition of Cerevel?
What is Cerevel Therapeutics' approach to treating neuroscience diseases?
Who are the contacts for media and investor inquiries at Cerevel Therapeutics?
